Abstract
Introduction Parkinson’s disease (PD) causes significant impairment due to both motor and non-motor symptoms, which severely impact patients’ health-related quality of life (HRQoL) and increase caregiver burden. Given the rising prevalence of PD in an aging population, particularly in Germany, the need for innovative and resource-efficient healthcare approaches is paramount. The complexity of PD symptoms and the necessity for individualised, multidisciplinary and digital health technology-based care are widely acknowledged; however, access to specialist care remains limited, particularly in rural areas. Current healthcare systems are frequently ill-equipped to deliver timely, personalised interventions. In response to these challenges, the ParkProReakt project aims to enhance PD care through a proactive, technology-enabled, multidisciplinary approach designed to improve patient HRQoL and alleviate caregiver burden.
Methods and analysis A randomised controlled trial will assess the efficacy and cost-effectiveness of ParkProReakt - a proactive, multidisciplinary, digitally supported care model for community-dwelling people with Parkinson’s disease (PwPD) - compared with standard care. We will recruit a total of 292 PwPD and their informal caregivers living in two diverse regions in Germany. The primary outcome measure will be patients’ HRQoL as measured by the PDQ-39, obtained at baseline, monthly and at completion of participation. Secondary outcomes comprise patients’ subjective wellbeing, incidence or change of long-term care needs, global cognition and disease progression, utilisation of health care services including hospitalisations, caregiver burden and health care costs. Statistical analysis will include t-tests for HRQoL changes, GLM for confounders, and multilevel models for centre effects. Secondary outcomes and cost-effectiveness (ICER) will be analysed similarly, using R and SPSS.
Ethics and dissemination The study protocol has been approved by the Ethics Committees of the Medical Associations of Hesse and Hamburg. The results of our study will be reported to the funding body and disseminated through scientific publications and presentations at national and international conferences.
Registration details This study was registered with the German Registry for Clinical Studies (DRKS) in both German and English - number: DRKS00031092.
What is already known on this topic Parkinson’s disease imposes severe motor and non-motor challenges on patients, impacting their quality of life and caregiver well-being. The complexity of symptoms necessitates individualized, multidisciplinary, and digital health-based approaches to care. Despite a recognized need for proactive, scalable interventions in Parkinson’s disease care, existing health systems have limited capacity for implementing these comprehensive, resource-efficient models effectively.
What this study adds This study introduces a novel, proactive, technology-based, patient-centered model of care for people with Parkinson’s disease, integrating wearable technology and an app to improve patient health-related quality of life. It rigorously assesses this model’s effectiveness and cost-efficiency in Germany.
How this study might affect research, practice or policy The study’s findings could inform policy on proactive digital care for aging populations, improve Parkinson’s disease care accessibility, and offer a framework for chronic disease management using patient-centered, cost-effective, and multidisciplinary approaches.
Competing Interest Statement
M.v.M., J.S., A.J.P.,K.N., I.W., A.M., M.N., P.F., M.O.A., A.P., M.I., C.T., P.M.O., UE.S. and N.A., are funded via the ParkProReakt project. I.W., D.B.,K.S., I.D., R.R., K.S., V.G., B.S., M.G., X.H., H.B., J.D., L.W., M.G. and L.K. declare no C.o.I.. E.K. has received grants from the German Ministry of Education and Research, General Joint Committee, Germany, the German Parkinson Society, and STADAPHARM GmbH; honoraria from Abbvie GmbH Germany; memodio GmbH Germany; licence fees from Prolog GmbH, Germany; all outside the submitted work. I.W. has received honoraria as a speaker at symposia sponsored by Stadapharm GmbH, Esteve Pharmaceuticals GmbH, Bial Germany GmbH, Fagron GmbH & Co.KG, Zambon GmbH, Bayer HealthCare AG, Nutrichem Diaet + Pharma GmbH, AbbVie Inc. He received payments as a consultant for Bial Germany GmbH, Fagron GmbH & Co.KG and Nutrichem Diaet + Pharma GmbH. He was reimbursed travel expenses by Esteve Pharmaceuticals GmbH for attending a congress in 2023. A.K.F. has received grants from the German Parkinson Society, the German Alzheimer's Society, the German Parkinson Foundation, STADAPHARM GmbH and the General Joint Committee Germany as well as honoraria from Springer Medizin Verlag GmbH, Heidelberg, Germany; Springer-Verlag GmbH, Berlin; ProLog Wissen GmbH, Cologne, Germany; Seminar- und Fortbildungszentrum Rheine, Germany; LOGOMANIA, Fendt & Sax GbR, Munich, Germany; LOGUAN, Ulm, Germany; dbs e.V., Moers, Germany; STADAPHARM GmbH, Bad Vilbel, Germany; NEUROPSY, St. Konrad, Austria; Multiple Sclerosis Society Vienna, Vienna, Austria; and Gossweiler Foundation, Bern, Switzerland. A.K.F. is author of the cognitive intervention series NEUROvitalis but receives no corresponding honoraria. C.E. received honoraria in the last 12 months for consultation or as a speaker from AbbVie Inc., Stadapharma Inc., Bial Inc., Bristol-Myers Squibb Inc. D.P. has received honoraria as a speaker at symposia sponsored by Boston Scientific Corp, Medtronic, AbbVie Inc, Zambon and Esteve Pharmaceuticals GmbH. D.P. received payments as a consultant for Boston Scientific Corp and Bayer, and a scientific grant from Boston Scientific Corp. D.P. has received honoraria as a speaker at symposia sponsored by Boston Scientific Corp, Medtronic, AbbVie Inc, Zambon and Esteve Pharmaceuticals GmbH. He received payments as a consultant for Boston Scientific Corp and Bayer, and he received a scientific grant from Boston Scientific Corp for a project entitled: Sensor-based optimisation of Deep Brain Stimulation settings in Parkinson's disease (COMPARE-DBS). Finally, D.P. was reimbursed by Esteve Pharmaceuticals GmbH and Boston Scientific Corp for travel expenses to attend congresses.
Clinical Trial
DRKS00031092
Funding Statement
This work was supported by the Innovationfund of the German Federal Joint Committee (Innovationsfonds des Gemeinsamen Bundesausschuss G-BA). Grant number [01NVF20019] and the Parkinson's Foundation. For information about the Innovation Fund: Innovationsausschuss beim Gemeinsamen Bundesausschuss P.O. Box 12 06 06 10596 Berlin E-mail: info{at}if.g-ba.de
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this study was obtained from the responsible state medical ethics committees in Hesse and Hamburg (Ref. 2022-3139-evBO and 2023-200762-BO-bet); Germany.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
